- Home
- ZBRA vs ASND Comparison
ZBRA vs ASND Comparison
Compare ZBRA & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZBRA | ASND |
|---|---|---|
| Founded | 1969 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4B | 16.2B |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ZBRA | ASND |
|---|---|---|
| Price | $364.72 | $248.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 16 |
| Target Price | ★ $321.88 | $281.50 |
| AVG Volume (30 Days) | ★ 812.9K | 478.0K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.54 | N/A |
| Revenue | ★ $5,396,000,000.00 | N/A |
| Revenue This Year | $13.27 | $96.35 |
| Revenue Next Year | $5.43 | $44.91 |
| P/E Ratio | $47.72 | ★ N/A |
| Revenue Growth | ★ 8.33 | N/A |
| 52 Week Low | $199.05 | $186.05 |
| 52 Week High | $386.23 | $282.15 |
Technical Indicators
Market Signals| Indicator | ZBRA | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 62.70 | N/A |
| Support Level | $350.36 | N/A |
| Resistance Level | $386.23 | N/A |
| Average True Range (ATR) | 9.74 | 0.00 |
| MACD | -4.60 | 0.00 |
| Stochastic Oscillator | 31.95 | 0.00 |
Price Performance
Historical ComparisonAbout ZBRA Zebra Technologies Corporation
Zebra Technologies is the largest provider of automatic identification and data capture technology to enterprises. Its solutions include barcode printers and scanners, mobile computers, and workflow optimization software. The firm primarily serves the retail, transportation logistics, manufacturing, and healthcare markets, designing custom solutions to improve efficiency at its customers.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.